This page has been archived on the Web
Information identified as archived is provided for reference, research or recordkeeping purposes. It is not subject to the Government of Canada Web Standards and has not been altered or updated since it was archived. Please contact us to request a format other than those available.
Teva-Tolterodine (2016-08-04)
- Starting date:
- August 4, 2016
- Posting date:
- August 11, 2016
- Type of communication:
- Drug Recall
- Subcategory:
- Drugs
- Hazard classification:
- Type II
- Source of recall:
- Health Canada
- Issue:
- Product Safety
- Audience:
- General Public, Healthcare Professionals, Hospitals
- Identification number:
- RA-59776
Affected products
- Teva-Tolterodine 1mg
- Teva-Tolterodine 2mg
Reason
Presence of fungal/mold organisms traced to raw material used in the formulation.
Depth of distribution
Pharmacies and Wholesalers Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland, Nova Scotia, Ontario, Quebec and Saskatchewan
Affected products
A. Teva-Tolterodine 1mg
DIN, NPN, DIN-HIM
DIN 02299593
Dosage form
Tablet
Strength
1mg
Lot or serial number
0T2003
Companies
- Recalling Firm
-
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
- Marketing Authorization Holder
-
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
B. Teva-Tolterodine 2mg
DIN, NPN, DIN-HIM
DIN 02299607
Dosage form
Tablet
Strength
2mg
Lot or serial number
0T3003
Companies
- Recalling Firm
-
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA
- Marketing Authorization Holder
-
Teva Canada Ltd.
30 Novopharm Court
Toronto
M1B 2K9
Ontario
CANADA